I agree that this site is using cookies. You can find further informations here.
X
Scalzulli, Potito Rosario
37  results:
Search for persons X
?
1

Real-World Outcome of Treatment with Single-Agent Ibrutinib..:

Mauro, Francesca Romana ; Scalzulli, Potito Rosario ; Scarfò, Lydia...
Cancers.  16 (2024)  6 - p. 1228 , 2024
Link: https://doi.org/10.3390/..
 
?
2

A real-world analysis of PD1 blockade from the Rete Ematolo..:

Gaudio, Francesco ; Loseto, Giacomo ; Bozzoli, Valentina...
Annals of Hematology.  102 (2023)  2 - p. 385-392 , 2023
Link: https://doi.org/10.1007/..
 
?
3

Real-world Outcomes of Relapsed/Refractory Diffuse Large B-..:

Argnani, Lisa ; Broccoli, Alessandro ; Pellegrini, Cinzia...
HemaSphere.  6 (2022)  12 - p. e798 , 2022
Link: https://doi.org/10.1097/..
 
?
4

Brentuximab vedotin consolidation after autologous stem cel..:

Massaro, Fulvio ; Pavone, Vincenzo ; Stefani, Piero Maria...
Hematological Oncology.  40 (2021)  1 - p. 32-40 , 2021
Link: https://doi.org/10.1002/..
 
?
5

Second-line administration of thrombopoietin receptor agoni..:

Carpenedo, Monica ; Baldacci, Erminia ; Baratè, Claudia...
Therapeutic Advances in Hematology.  12 (2021)  - p. 204062072110483 , 2021
Link: https://doi.org/10.1177/..
 
?
6

Log reduction of leukemic cells and minimal residual diseas..:

Rossi, Giovanni ; Giambra, Vincenzo ; de Waure, Chiara...
Cytometry Part B: Clinical Cytometry.  102 (2021)  1 - p. 26-33 , 2021
Link: https://doi.org/10.1002/..
 
?
7

Brentuximab vedotin in association with bendamustine in ref..:

Iannitto, Emilio ; Romano, Alessandra ; Scalzulli, Potito Rosario...
European Journal of Haematology.  104 (2020)  6 - p. 581-587 , 2020
Link: https://doi.org/10.1111/..
 
?
8

Minimal residual disease and log‐reduction of plasma cells ..:

Rossi, Giovanni ; Falcone, Antonietta Pia ; Minervini, Maria Marta...
Cytometry Part B: Clinical Cytometry.  96 (2018)  3 - p. 195-200 , 2018
Link: https://doi.org/10.1002/..
 
?
9

Predictive role of minimal residual disease and log clearan..:

Rossi, Giovanni ; Minervini, Maria Marta ; Melillo, Lorella...
Annals of Hematology.  , 2014
Link: https://doi.org/10.1007/..
 
?
10

Low impact of cardiovascular adverse events on anagrelide t..:

Gugliotta, Luigi ; Tieghi, Alessia ; Tortorella, Giovanni...
Leukemia Research.  35 (2011)  12 - p. 1557-1563 , 2011
Link: https://doi.org/10.1016/..
 
?
11

Rituximab to treat chronic lymphoproliferative disorder-ass..:

D'Arena, Giovanni ; Vigliotti, Maria Luigia ; Dell'Olio, Matteo...
European Journal of Haematology.  82 (2009)  3 - p. 235-239 , 2009
Link: https://doi.org/10.1111/..
 
?
12

Outcome of 122 pregnancies in essential thrombocythemia pat..:

Melillo, Lorella ; Tieghi, Alessia ; Candoni, Anna...
American Journal of Hematology.  84 (2009)  10 - p. 636-640 , 2009
Link: https://doi.org/10.1002/..
 
?
13

Attenuated doses of rituximab for the treatment of adults w..:

D'arena, Giovanni ; Scalzulli, Potito Rosario ; Nobile, Michele...
American Journal of Hematology.  83 (2008)  8 - p. 686-687 , 2008
Link: https://doi.org/10.1002/..
 
?
14

Peg-filgrastim versus filgrastim after autologous stem cell..:

Musto, Pellegrino ; Scalzulli, Potito Rosario ; Terruzzi, Elisabetta...
Leukemia Research.  31 (2007)  11 - p. 1487-1493 , 2007
Link: https://doi.org/10.1016/..
 
?
15

Bortezomib (Velcade) for progressive myeloma after autologo..:

Musto, Pellegrino ; Falcone, Antonietta ; Sanpaolo, Grazia...
Leukemia Research.  30 (2006)  3 - p. 283-285 , 2006
Link: https://doi.org/10.1016/..
 
1-15